SCHEMBL6767398

SCHEMBL6767398

O=C1Cc2ccccc2N1c1cccc(F)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.68
FAAH O00519 1/20 0.51
MGLL Q99685 1/20 0.51
GAA P10253 4/20 0.51
ALDH1A1 P00352 3/20 0.51
MAPT P10636 2/20 0.51
POLB P06746 1/20 0.51
SLC6A2 P23975 1/20 0.49
KMT2A Q03164 5/20 0.49
MEN1 O00255 4/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
CASP6 P55212 4/20 0.48
PKM P14618 1/20 0.44
TLR9 Q9NR96 1/20 0.44
PGR P06401 1/20 0.42
LMNA P02545 1/20 0.41
TNKS O95271 1/20 0.41
PER2 O15055 1/20 0.41
CRY2 Q49AN0 1/20 0.41
NOTUM Q6P988 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6763292 0.83 HPGD (0.70) HPGDMGLLGAAALDH1A1MAPT
SCHEMBL6765903 0.82 HPGD (0.74) HPGDMGLLGAAALDH1A1POLB
SCHEMBL143970 0.81 HPGD (1.00) HPGDGAAALDH1A1KMT2AMEN1
SCHEMBL31422646 0.81 HPGD (1.00) HPGDGAAALDH1A1KMT2AMEN1
SCHEMBL6772536 0.81 HPGD (0.68) HPGDMGLLGAAALDH1A1MAPT
SCHEMBL7009115 0.81 HPGD (0.62) HPGDGAAALDH1A1POLBKMT2A
SCHEMBL10398763 0.79 HPGD (0.65) HPGDGAAALDH1A1MAPTPOLB
SCHEMBL6772611 0.79 HPGD (0.64) HPGDMGLLGAAALDH1A1MAPT
SCHEMBL28240877 0.78 HPGD (0.62) HPGDFAAHMGLLGAAALDH1A1
SCHEMBL6525622 0.77 MEN1 (0.56) HPGDFAAHMGLLGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US claimed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP claimed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US claimed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO claimed
US-4977178-A Method of treating anxiety and depression with 1-phenyl-2(1H,3H)-indolone psycho-therapeutic agents PFIZER INC. (US) 1990-12-11 US disclosed
US-4879391-A 1-Phenyl-2(1H,3H)-indolone psychotherapeutic agents PFIZER INC. (US) 1989-11-07 US disclosed
US-4861880-A 1-phenyl-2(1H,3H)-indolone psycho-therapeutic agents PFIZER INC. (US) 1989-08-29 US disclosed
EP-0104860-B1 1-PHENYL-2(1H,3H)-INDOLONE PSYCHO-THERAPEUTIC AGENTS PFIZER INC. (US) 1987-03-18 EP disclosed
US-4476307-A Heteroylidene indolone compounds PFIZER INC. (US) 1984-10-09 US disclosed
EP-0104860-A1 1-Phenyl-2(1H,3H)-indolone psycho-therapeutic agents PFIZER INC. (US) 1984-04-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 HPGD 1764/4885FAAH 3530/4885MGLL 3604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.